AstraZeneca backs Pangaea’s AI platform to scale precision healthcare

Pangaea Data, a health-tech firm specialising in patient-intelligence platforms, announced a strategic, multi-year partnership with AstraZeneca to deploy multimodal artificial intelligence in clinical settings. The goal is to bring AI-driven, data-rich clinical decision-making to scale, improving how patients are identified, diagnosed, treated and connected to therapies or clinical trials.

The collaboration will see AstraZeneca sponsoring the configuration, validation and deployment of Pangaea’s enterprise-grade platform, which merges large-scale clinical, imaging, genomic, pathology and real-world data. It will also leverage generative and predictive AI capabilities from Microsoft and NVIDIA for model training and deployment.

Among the planned applications are supporting point-of-care treatment decisions and identifying patients who are undiagnosed, undertreated or misdiagnosed, across diseases ranging from chronic conditions to cancer.

Pangaea’s CEO said the partnership aims to efficiently connect patients to life-changing therapies and trials in a compliant, financially sustainable way. For AstraZeneca, the effort reflects a broader push to integrate AI-driven precision medicine across its R&D and healthcare delivery pipeline.

From a policy and health-governance standpoint, this alliance is important. It demonstrates how multimodal AI, combining different data types beyond standard medical records, is being viewed not just as a research tool, but as a potentially transformative element of clinical care.

Would you like to learn more about AI, tech and digital diplomacy? If so, ask our Diplo chatbot!